# Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma

Source: https://onco.cc/trials/nct07787429/  
OnCo record `nct07787429` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Mifamurtide and Sorafenib in Osteosarcoma, run by Anna Raciborska, now recruiting.

## Summary

Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma is a phase 2 interventional study registered as NCT07787429 by Anna Raciborska, with 40 participants planned, started 2026-04-01 and due to reach its primary completion in 2033-07-31. Interventions recorded: Mifamurtide, Sorafenib. Conditions recorded: Osteosarcoma.

Linked to the drug Mifamurtide because the registry names it among its interventions and Osteosarcoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07787429
- Phase: 2
- Setting: Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma (DRAGONFLY)
- Sponsor: Anna Raciborska
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07787429: https://clinicaltrials.gov/study/NCT07787429

## Connected records

- cancers: [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/)
- drugs: [Mifamurtide](https://onco.cc/drugs/mifamurtide/), [Sorafenib](https://onco.cc/drugs/sorafenib/)

---
JSON: https://onco.cc/api/v1/entities/nct07787429.json